» Articles » PMID: 33424518

Construction of Radiation Surviving/Resistant Lung Cancer Cell Lines with Equidifferent Gradient Dose Irradiation

Overview
Journal Dose Response
Publisher Sage Publications
Date 2021 Jan 11
PMID 33424518
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Radiotherapy plays an increasingly crucial role in the treatment of non-small cell lung cancer (NSCLC). Local tumor recurrence and tumor progression caused by intratumoral heterogeneity induced radiotherapy resistance remain the primary causes of radiotherapy failure. However, the lack of a suitable cell line model has hampered the exploration of the dynamic mechanisms of radiation resistance. We established 3 groups of equidifferent gradient dose irradiation surviving/resistant human lung cancer cell lines based on A549, H520, and H460 cells with clinical conventional fractionated radiotherapy (CFRT) (2 Gy × 20 F, 2 Gy × 30 F, and 2 Gy × 40 F). The radiosensitivity of the cells was detected by clone formation assay, EDU cell proliferation assay, neutral comet assay, and γ-H2AX immunofluorescence staining. The radiosensitivity and proliferation viability were increased in a received dose-dependent manner. Compared with parental cells, DNA double-strand breaks (DSBs) in cell lines that received higher-dose irradiation were significantly reduced. We successfully constructed equidifferent gradient dose irradiation surviving/resistant NSCLC cell lines whose radiation surviving and resistant abilities were increased in a received dose-dependent manner. This preclinical cell model could be used to dynamically observe and detect the radiation surviving/resistant biomarkers during radiotherapy stress, elucidate the mechanism of radiation resistance.

Citing Articles

Efficiency of moderately hypofractionated radiotherapy in NSCLC cell model.

Ludeking M, Stemwedel K, Ramachandran D, Grosche S, Christiansen H, Merten R Front Oncol. 2024; 14:1293745.

PMID: 38720797 PMC: 11076864. DOI: 10.3389/fonc.2024.1293745.


Generation and Characterization of an Isogenic Cell Line Model of Radioresistant Esophageal Adenocarcinoma.

Cannon A, Maher S, Lynam-Lennon N Methods Mol Biol. 2023; 2645:139-152.

PMID: 37202615 DOI: 10.1007/978-1-0716-3056-3_6.


The development of radioresistant oral squamous carcinoma cell lines and identification of radiotherapy-related biomarkers.

Huang J, Meng Q, Liu R, Li H, Li Y, Yang Z Clin Transl Oncol. 2023; 25(10):3006-3020.

PMID: 37029240 DOI: 10.1007/s12094-023-03169-7.


Extracellular matrix stiffness mediates radiosensitivity in a 3D nasopharyngeal carcinoma model.

Fang Y, Liang S, Gao J, Wang Z, Li C, Wang R Cancer Cell Int. 2022; 22(1):364.

PMID: 36403050 PMC: 9675143. DOI: 10.1186/s12935-022-02787-5.


Effectiveness of hypofractionated and normofractionated radiotherapy in a triple-negative breast cancer model.

Grosche S, Bogdanova N, Ramachandran D, Ludeking M, Stemwedel K, Christiansen H Front Oncol. 2022; 12:852694.

PMID: 36387199 PMC: 9646794. DOI: 10.3389/fonc.2022.852694.


References
1.
Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

2.
Kim T, Hong D, Park J, Hong S . CB11, a novel purine-based PPARɣ ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells. Br J Cancer. 2020; 123(12):1737-1748. PMC: 7723055. DOI: 10.1038/s41416-020-01088-w. View

3.
Arriagada R, Auperin A, Burdett S, Higgins J, Johnson D, Le Chevalier T . Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010; 375(9722):1267-77. PMC: 2853682. DOI: 10.1016/S0140-6736(10)60059-1. View

4.
Li J, Li Y, Jin W, Yang Q, Shao Z, Tian X . ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL. J Exp Clin Cancer Res. 2012; 31:102. PMC: 3541995. DOI: 10.1186/1756-9966-31-102. View

5.
Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View